Euglycemic diabetic ketoacidosis can challenge one of the most familiar clinical shortcuts in diabetes care: DKA should come with markedly elevated glucose. In patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors, however, dangerous ketoacidosis may develop while glucose remains normal or only modestly elevated. As a result, euglycemic DKA in patients …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.